Discover

VTGN
Vistagen Therapeutics, Inc.
0.24
2 x 0.18
2 x 0.28
bid
ask
+
0.02
7.52%
2 @ 04:00 PM
0.23 -0.01 (4.73%)
Ytd-63.18%
1y-88.09%
0.21
day range
0.26
0.20
52 week range
5.14
Open0.22Prev Close0.23Low0.21High0.26Mkt Cap9.97M
Vol14.21MAvg Vol1.90MEPS-1.83P/EN/AForward P/E-1.49
Beta0.78Short Ratio1.69Inst. Own53.63%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg0.60200-d Avg1.731yr Est13.00

VTGN News

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
benzinga.com
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fased

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
benzinga.com
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-pat

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#

Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
benzinga.com
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June

US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.

US Stocks Mixed; Home Prices Increase 1.1% In April
benzinga.com
US Stocks Mixed; Home Prices Increase 1.1% In April

US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up

benzinga.com
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Tre

PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical tr

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
businesswire.com
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

benzinga.com
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimat

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the